TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ).
Jacobio Pharmaceuticals Group Co., Ltd. announced an increase in shareholdings by parties acting in concert, who purchased 854,400 shares between July 16 and July 18, 2025, at an average price of HK$5.88 per share. This acquisition reflects the parties’ confidence in the company’s growth potential and long-term investment value, with their total holdings now representing approximately 25.32% of the company’s issued shares. The transaction was conducted in compliance with relevant laws and regulations, indicating a positive outlook for the company’s future development.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and commercialization of innovative drugs, with a particular emphasis on oncology treatments.
Average Trading Volume: 6,599,141
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.3B
For a thorough assessment of 1167 stock, go to TipRanks’ Stock Analysis page.